Literature DB >> 26297548

MiR-454 inhibited cell proliferation of human glioblastoma cells by suppressing PDK1 expression.

Baojun Fang1, Jianxin Zhu1, Yunhua Wang2, Fengyang Geng2, Gang Li3.   

Abstract

It has been well documented that aberrant expression of microRNAs is associated with carcinogenesis of glioblastoma (GBM), however the underlying mechanisms are not clear. In this present study, we aimed to clarify the biological function of miR-454 in GBM. MiR-454 was identified to be significantly down-regulated in GBM primary tumors and cell lines. Overexpression of miR-454 in GBM cells resulted in arresting cells at G0/G1 phase and thus inhibiting cell proliferation. Bioinformatic analysis predicted 3-phosphoinositide-dependent protein kinase-1 (PDK1) as a target of miR-454 which acted as a tumor promoter gene. Increased miR-454 significantly repressed PDK1 expression, and then regulating cell proliferation and cell cycle regulators, down-regulation of Cyclin D1 and p-pRb and p21 was up-regulated. Taken together, our study has revealed miR-454 as a tumor suppressor in GBM.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cell cycle; Cell proliferation; Glioblastoma; MiR-454; PDK1

Mesh:

Substances:

Year:  2015        PMID: 26297548     DOI: 10.1016/j.biopha.2015.07.029

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  12 in total

Review 1.  Targeting IGF1R pathway in cancer with microRNAs: How close are we?

Authors:  Arathy S Kumar; Suresh K Rayala; Ganesh Venkatraman
Journal:  RNA Biol       Date:  2018-02-01       Impact factor: 4.652

Review 2.  Glucose transport: meeting the metabolic demands of cancer, and applications in glioblastoma treatment.

Authors:  Collin M Labak; Paul Y Wang; Rishab Arora; Maheedhara R Guda; Swapna Asuthkar; Andrew J Tsung; Kiran K Velpula
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

3.  miR-130a Deregulates PTEN and Stimulates Tumor Growth.

Authors:  Huijun Wei; Ri Cui; Julian Bahr; Nicola Zanesi; Zhenghua Luo; Wei Meng; Guang Liang; Carlo M Croce
Journal:  Cancer Res       Date:  2017-09-21       Impact factor: 12.701

4.  Silencing miR-454 suppresses cell proliferation, migration and invasion via directly targeting MECP2 in renal cell carcinoma.

Authors:  Huan Liu; Qun-Long Liu; Ting-Shuai Zhai; Jun Lu; Yun-Ze Dong; Yun-Fei Xu
Journal:  Am J Transl Res       Date:  2020-08-15       Impact factor: 4.060

5.  Integrated genomic analysis of survival outliers in glioblastoma.

Authors:  Sen Peng; Harshil Dhruv; Brock Armstrong; Bodour Salhia; Christophe Legendre; Jeffrey Kiefer; Julianna Parks; Selene Virk; Andrew E Sloan; Quinn T Ostrom; Jill S Barnholtz-Sloan; Nhan L Tran; Michael E Berens
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

6.  Knockdown of long non-coding RNA HOTAIR increases miR-454-3p by targeting Stat3 and Atg12 to inhibit chondrosarcoma growth.

Authors:  Xing Bao; Tingting Ren; Yi Huang; Kunkun Sun; Shidong Wang; Kuisheng Liu; Bingxin Zheng; Wei Guo
Journal:  Cell Death Dis       Date:  2017-02-09       Impact factor: 8.469

7.  MicroRNA-454-3p inhibits cervical cancer cell invasion and migration by targeting c-Met.

Authors:  Yan Guo; Min Tao; Min Jiang
Journal:  Exp Ther Med       Date:  2018-01-08       Impact factor: 2.447

8.  MicroRNA-454 regulates stromal cell derived factor-1 in the control of the growth of pancreatic ductal adenocarcinoma.

Authors:  Yue Fan; Li-Li Xu; Chen-Ye Shi; Wei Wei; Dan-Song Wang; Ding-Fang Cai
Journal:  Sci Rep       Date:  2016-03-15       Impact factor: 4.379

9.  Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5.

Authors:  Guangru Xu; Hongxing Zhu; Minghui Zhang; Jinhua Xu
Journal:  Int J Mol Med       Date:  2017-10-31       Impact factor: 4.101

10.  miR-454 suppresses the proliferation and invasion of ovarian cancer by targeting E2F6.

Authors:  Yunhe An; Jun Zhang; Xiaoyan Cheng; Baoming Li; Yanjie Tian; Xiaoli Zhang; Fangqi Zhao
Journal:  Cancer Cell Int       Date:  2020-06-12       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.